Tufts University proves voltage restoration overrides cancer at the genetic level
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | The argument is no longer ours to make. The establishment is making it for us. |
|
|
| |
| |
|
| | Professor Michael Levin, Harvard-trained, Tufts University, Cell journal, 2021: restoring bioelectric voltage overrides oncogenic mutations. The cancer mutation is present. The cancer does not grow. Because the voltage was restored. That is exactly what CellSonic does |
|
Cancer is an electrical failure requiring an electrical correction. This has been known since 1970. It has been demonstrated independently by scientists on 3 continents across 9 decades. In February 2026, the FDA validated it for the fourth time, in the form of an approved competitor technology called Novocure Tumor Treating Fields. |
|
|
| |
| |
|
| | Novocure is running trials to expand into gastric cancer, ovarian cancer, and liver cancer. CellSonic already treats all of them. Novocure is spending hundreds of millions to reach a destination CellSonic is already at. |
|
National Cancer Institute (NCI) |
|
In September 2024 the National Cancer Institute convened a formal conference on Cancer Bioelectricity. The same mechanism CellSonic has applied since 1987. The United States government is now studying it. |
|
|
| |
| |
|
| | The World Spent $223 Billion on Cancer Medicine in 2023 |
|
IQVIA projects $409 billion by 2028 |
|
|
| |
| |
|
| | 90% of US $4.9T/yr Healthcare Spend goes to Chronic Disease. |
|
Total bill between 2024-2039 is $47 Trillion |
|
|
| |
| |
|
| | Welcome to the End of Chronic Disease |
|
The argument is no longer ours to make. The establishment is making it for us.
Sapiens Shield launches this year. The question is not whether this works. The question is who moves first. |
|
|
| |
| |
|
|
